Trials will have very strict parameters and testing is limited within these. Nice parallel thinking though.
As an antiviral it should have other applications, but these will need to be tested separately. Logically, you would need a cohort suffering from another ailment for the testing to be valid.
$30 Billion Deal, page-4517
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $43.30M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $13.69K | 278.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 46070 | 1 |
View Market Depth
| Last trade - 15.37pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.0¢ |
Change
-0.002 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 4.9¢ | 5.0¢ | 4.9¢ | 61814 | ||
| Last updated 13.21pm 17/06/2024 ? | |||||
| BIT (ASX) Chart |
